<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652793</url>
  </required_header>
  <id_info>
    <org_study_id>2014-002720-27</org_study_id>
    <nct_id>NCT02652793</nct_id>
  </id_info>
  <brief_title>Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia</brief_title>
  <acronym>Osteosimply014</acronym>
  <official_title>Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Garcia Cinca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacion Clinic per a la Recerca Biomédica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 48-week, open label, non comparative prospective trial in stable chronic human
      immunodeficiency virus-infected patients having achieved complete virological suppression for
      more than 24 weeks (human immunodeficiency virus-1 RNA &lt;50 c/ml) switching from an
      antiretroviral regimen containing tenofovir and lamivudine or emtricitabine and boosted
      protease inhibitor to boosted atazanavir and lamivudine Study visits will take place at
      screening, baseline, weeks 4, 12, 24, and 48.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bone mineral density by dual-energy X-ray absorptiometry in human immunodeficiency virus-infected adults with hip or spine T-score between &lt; -1.0 and &gt;-2.5 by dual-energy X-ray absorptiometry</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients free of virologic failure (confirmed viral load≥ 50 copies/mL)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover markers in blood: urinary N-terminal telopeptide of type-1 collagen</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone turnover markers in blood: bone-specific alkaline phosphatase</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction parameter: estimated glomerular filtration rate</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction parameter: phosphorus in blood sample</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: glucose in urine</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: protein in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: albumin in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: creatinin in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: phosphorus in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: beta-2 microglobulin in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renald disfunction, tubule dysfunction, parameter: N-Acetyl-β-D Glucosaminidase in urine samples</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will switch their current antiretroviral regimen to a boosted atazanavir and lamivudine once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boosted atazanavir</intervention_name>
    <description>Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Lamivudine 300 mg once dailly</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Human immunodeficiency virus-1-infected subjects with age ≥18 years old

          -  Hip or spine T-scores between &lt; -1.0 and &gt;-2.5 by dual-energy X-ray absorptiometry (in
             the previous 24 weeks)

          -  Stable antiretroviral treatment based on tenofovir and lamivudine or emtricitabine and
             boosted protease inhibitor for at least 24 weeks.

          -  Having plasma human immunodeficiency virus-1 RNA &lt;50 copies/mL for at least the
             previous 24 weeks, including at least two samples.

        Exclusion Criteria:

          -  Pregnancy, breast-feeding status or plans for pregnancy in the short term

          -  Primary genotypic resistance mutations and/or previous virological failures to
             atazanavir or lamivudine/emtricitabine

          -  Chronic hepatitis B infection

          -  Patients with indication for therapy for the prevention of bone fractures

          -  25-OH vitamin D deficiency (&lt; 10ng/mL)

          -  Hypogonadism (low total testosterone according to local reference range)

          -  Hypothyroidism (low T4 and increased thyroid stimulating hormone levels according to
             local reference ranges)

          -  Hyperparathyroidism (increased parathyroid hormone level with hypercalcaemia according
             to local reference ranges)

          -  Having received oral corticosteroids or inhaled fluticasone (daily doses higher than 5
             mg/d prednisone equivalent for 3 months or more)

          -  Using anti-resorptive therapy (Calcium and vitamin D supplements are encouraged but
             not mandated)

          -  Body mass index lower than 19
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jose Luís Blanco, MD</last_name>
    <phone>+34 93 227 54 00</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Garcia Cinca</last_name>
    <email>dgarcia@clinic.ub.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Blanco, MD</last_name>
      <phone>+34 93 227 54 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2015</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>August 16, 2016</last_update_submitted>
  <last_update_submitted_qc>August 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>David Garcia Cinca</investigator_full_name>
    <investigator_title>Clinical Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

